Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2777117 | 0.85 | MEN1 (0.56) | RAB9ASMN1; SMN2NPC1DRD2DRD4 | |
| SCHEMBL2776702 | 0.82 | HRH3 (0.41) | DRD2DRD4HRH3NUDT1APP | |
| SCHEMBL2776946 | 0.74 | HRH3 (0.44) | HRH3NUDT1ALDH1A1 | |
| SCHEMBL14553221 | 0.74 | HRH3 (0.44) | DRD2DRD4HRH3ALDH1A1CYP2C19 | |
| SCHEMBL2777149 | 0.74 | HRH3 (0.41) | DRD2DRD4HRH3APP | |
| SCHEMBL14619655 | 0.73 | DRD2 (0.47) | DRD2DRD4HRH3POLBALDH1A1 | |
| SCHEMBL2778635 | 0.72 | DRD2 (0.44) | DRD2DRD4HRH3APP | |
| SCHEMBL3183236 | 0.70 | DRD2 (0.47) | DRD2DRD4HRH3APP | |
| SCHEMBL7363505 | 0.70 | SMN1; SMN2 (0.62) | RAB9ASMN1; SMN2NPC1NUDT1MEN1 | |
| SCHEMBL4528068 | 0.70 | NPC1 (0.67) | RAB9ASMN1; SMN2NPC1NUDT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | RAB9A 1469/4885SMN1; SMN2 2931/4885NPC1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.